[go: up one dir, main page]

PA8748101A1 - Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus - Google Patents

Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus

Info

Publication number
PA8748101A1
PA8748101A1 PA20078748101A PA8748101A PA8748101A1 PA 8748101 A1 PA8748101 A1 PA 8748101A1 PA 20078748101 A PA20078748101 A PA 20078748101A PA 8748101 A PA8748101 A PA 8748101A PA 8748101 A1 PA8748101 A1 PA 8748101A1
Authority
PA
Panama
Prior art keywords
treatment
disease
compounds
preparation
oxazolopiridins
Prior art date
Application number
PA20078748101A
Other languages
English (en)
Inventor
Gerspacher Marc
Furet Pascal
Vangrevelinghe Eric
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37717673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8748101(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PA8748101A1 publication Critical patent/PA8748101A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE BENZOXAZOL 2,7-DISUSTITUIDO Y OXAZOLO-[5,4-C]-PIRIDINA 2,4-DISUSTITUIDA DE LA FORMULA I QUE SE DA MAS ADELANTE, ASI COMO A SALES DE LOS MISMOS, A PROCESOS PARA SU PREPARACION, A LA APLICACION DE LOS MISMOS EN UN PROCESO PARA EL TRATAMIENTO DEL CUERPO HUMANO O ANIMAL, ESTOS COMPUESTOS PARA UTILIZARSE EN EL TRATAMIENTO (INCLUYENDO PROFILAXIS) DEL CUERPO DEL ANIMAL, EN ESPECIAL HUMANO (ESPECIALMENTE CON RESPECTO A UNA ENFERMEDAD PROLIFERATIVA), EL USO DE LOS MISMOS - SOLOS O EN COMBINACION CON UNO O MAS COMPUESTOS FARMACEUTICAMENTE ACTIVOS DIFERENTES - PARA EL TRATAMIENTO EN ESPECIAL DE UNA ENFERMEDAD MEDIADA POR LA CINASA DE PROTEINA TIROSINA (TAL COMO UNA ENFERMEDAD TUMORAL) O PARA LA FABRICACION DE UNA PREPARACION FARMACEUTICA PARA UTILIZARSE EN EL TRATAMIENTO DE ESTA ENFERMEDAD, UN METODO PARA EL TRATAMIENTO DE ESTA ENFERMEDAD Y UNA PREPARACION FARMACEUTICA PARA EL TRATAMIENTO DE UNA ENFERMEDAD COMO SE MENCIONA. LOS COMPUESTOS SON DE LA FORMULA I: EN DONDE LOS SIMBOLOS SON COMO SE DEFINEN EN LA DESCRIPCION. LOS COMPUESTOS INHIBEN, POR EJEMPLO, JAK2 Y JAK3.
PA20078748101A 2006-09-15 2007-09-14 Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus PA8748101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06120733A EP1900729A1 (en) 2006-09-15 2006-09-15 Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors

Publications (1)

Publication Number Publication Date
PA8748101A1 true PA8748101A1 (es) 2009-08-26

Family

ID=37717673

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20078748101A PA8748101A1 (es) 2006-09-15 2007-09-14 Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus

Country Status (30)

Country Link
US (1) US8629168B2 (es)
EP (2) EP1900729A1 (es)
JP (1) JP5325105B2 (es)
KR (1) KR20090064389A (es)
CN (1) CN101516860B (es)
AR (1) AR062786A1 (es)
AT (1) ATE532774T1 (es)
AU (1) AU2007296916B2 (es)
BR (1) BRPI0716841A2 (es)
CA (1) CA2660987A1 (es)
CL (1) CL2007002669A1 (es)
CO (1) CO6150142A2 (es)
CR (1) CR10639A (es)
EA (1) EA200900388A1 (es)
ES (1) ES2377148T3 (es)
GT (1) GT200900056A (es)
IL (1) IL196860A0 (es)
MA (1) MA30723B1 (es)
MX (1) MX2009002812A (es)
NO (1) NO20091469L (es)
PA (1) PA8748101A1 (es)
PE (1) PE20080842A1 (es)
PL (1) PL2066647T3 (es)
PT (1) PT2066647E (es)
SM (1) SMP200900023B (es)
TN (1) TN2009000070A1 (es)
TW (1) TW200819444A (es)
UY (1) UY30587A1 (es)
WO (1) WO2008031594A1 (es)
ZA (1) ZA200900477B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
JP5449346B2 (ja) * 2008-07-15 2014-03-19 サノフイ Edg−1受容体アゴニストとしてのオキサゾロピリミジン類
EP2323978A1 (en) * 2008-08-12 2011-05-25 Takeda Pharmaceutical Company Limited Amide compound
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
KR101361027B1 (ko) 2008-11-28 2014-02-11 코와 가부시키가이샤 피리딘-3-카르복시아미드 유도체
EP2518054A1 (en) 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amide compound
AR079980A1 (es) * 2010-01-13 2012-03-07 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2,5,7
CA2828483A1 (en) 2011-02-23 2012-11-01 Intellikine, Llc Combination of kinase inhibitors and uses thereof
US8907093B2 (en) * 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
CN103102359B (zh) * 2011-11-15 2016-11-09 江苏先声药业有限公司 嘧啶类化合物及其应用
MX2014006479A (es) 2011-11-30 2015-01-22 Univ Emory Inhibidores antivirales de la janus cinasa utiles en el tratamiento o prevencion de infecciones retrovirales y otras infecciones virales.
WO2014075318A1 (zh) * 2012-11-19 2014-05-22 江苏先声药业有限公司 嘧啶类化合物及其应用
JP6360881B2 (ja) 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. 触媒的mtorc1/2阻害薬及びオーロラaキナーゼの選択的阻害薬の組合せ
CN103664759A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-羟基-2-硝基吡啶的制备方法
DK3102195T3 (da) 2014-02-03 2021-12-20 Quadriga Biosciences Inc Beta-substituerede beta-aminosyrer og analoger som kemoterapeutiske midler
BR112016017993A2 (pt) 2014-02-03 2017-08-08 Quadriga Biosciences Inc Gama-aminoácidos beta-substituídos e análogos como agentes quimioterapêuticos
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
EP3331851A1 (en) 2015-08-03 2018-06-13 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof
WO2021062163A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
CA3177830A1 (en) 2020-05-13 2021-11-18 Maria BECONI Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
WO2022251597A1 (en) 2021-05-28 2022-12-01 Verge Analytics, Inc. Methods of treating neurological disorders with modulators of ribosomal protein s6 kinase alpha-1 (rsk1) and ribosomal protein s6 kinase alpha-3 (rsk2)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1382339E (pt) * 1999-12-10 2008-02-06 Pfizer Prod Inc Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
GB0402140D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
EP1674467A1 (en) * 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
CN101253171B (zh) 2005-09-02 2011-06-15 霍夫曼-拉罗奇有限公司 苯并噁唑、噁唑并吡啶、苯并噻唑和噻唑并吡啶衍生物
RU2009105826A (ru) * 2006-07-21 2010-08-27 Новартис АГ (CH) 2,4-ди(ариламино)питимидин-5-карбоксамидные соединения в качестве ингибиторов jak-киназ

Also Published As

Publication number Publication date
AR062786A1 (es) 2008-12-03
NO20091469L (no) 2009-04-15
IL196860A0 (en) 2009-11-18
JP5325105B2 (ja) 2013-10-23
SMP200900023B (it) 2009-07-14
ATE532774T1 (de) 2011-11-15
CR10639A (es) 2009-07-03
JP2010503629A (ja) 2010-02-04
UY30587A1 (es) 2008-05-02
EP2066647B1 (en) 2011-11-09
AU2007296916B2 (en) 2011-10-06
CL2007002669A1 (es) 2008-05-09
TW200819444A (en) 2008-05-01
CN101516860A (zh) 2009-08-26
PT2066647E (pt) 2012-01-17
MX2009002812A (es) 2009-03-31
US20100009978A1 (en) 2010-01-14
EA200900388A1 (ru) 2009-08-28
WO2008031594A1 (en) 2008-03-20
EP2066647A1 (en) 2009-06-10
TN2009000070A1 (en) 2010-08-19
GT200900056A (es) 2011-11-08
CN101516860B (zh) 2012-06-27
AU2007296916A1 (en) 2008-03-20
BRPI0716841A2 (pt) 2013-10-01
ZA200900477B (en) 2010-01-27
PL2066647T3 (pl) 2012-04-30
CO6150142A2 (es) 2010-04-20
US8629168B2 (en) 2014-01-14
PE20080842A1 (es) 2008-08-11
EP1900729A1 (en) 2008-03-19
KR20090064389A (ko) 2009-06-18
SMAP200900023A (it) 2009-05-11
ES2377148T3 (es) 2012-03-22
CA2660987A1 (en) 2008-03-20
MA30723B1 (fr) 2009-09-01

Similar Documents

Publication Publication Date Title
PA8748101A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
UY29199A1 (es) Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones
GT200900154A (es) Derivados de 2,3-dihidroimidozo [1,2-c] quinizolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
UY29633A1 (es) Derivados de oxindol
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
DOP2010000013A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
PA8587101A1 (es) Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos
UY29246A1 (es) Nuevos compuestos
ECSP088828A (es) 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa csf-1r
ECSP088869A (es) Derivados de 2-pirazinona para el tratamiento de enfermedades o condiciones en donde resulta beneficiosa la inhibición de la actividad de la elastasa neutrofílica
UY29093A1 (es) Derivados de 4-oxo-3. 4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones que los contienen, procesos de preparación y aplicaiones.
ECSP10010427A (es) DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET
ECSP055899A (es) Pirimidinas inhibidoras de chk, pdk y akt, su producción y su uso como agentes farmacéuticos
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
UY29300A1 (es) Compuestos quimicos
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PA8623001A1 (es) Compuestos de quinolina sustituidos
ECSP056246A (es) DERIVADOS DE PIRROLO [3,4-c]PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
UY29092A1 (es) Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
GT200600089A (es) Compuestos organicos
UY31805A (es) Agonistas m1, composiciones farmacéuticas de los mismos, procesos para su preparacion y sus usos para el tratamiento del dolor